Research Analysts Issue Forecasts for KALA BIO Q3 Earnings

Key Points

• HC Wainwright has revised its Q3 2025 EPS estimate for KALA BIO to ($1.55), reflecting an increase from the previous estimate of ($1.59) and maintains a "Buy" rating with a $12.00 price target.
• The company recently reported Q2 earnings of ($1.71) EPS, which surpassed analysts' expectations, as it beat the consensus estimate of ($1.82) by $0.11.
• Institutional investors are actively engaging with KALA BIO, with several hedge funds increasing their stake, leading to a total of 24.61% of the company's stock being owned by these investors.

KALA BIO, Inc. (NASDAQ:KALA - Free Report) - Investment analysts at HC Wainwright increased their Q3 2025 earnings per share (EPS) estimates for KALA BIO in a note issued to investors on Wednesday, August 13th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($1.55) for the quarter, up from their prior estimate of ($1.59). HC Wainwright currently has a "Buy" rating and a $12.00 target price on the stock. The consensus estimate for KALA BIO's current full-year earnings is ($10.84) per share. HC Wainwright also issued estimates for KALA BIO's Q4 2025 earnings at ($1.32) EPS, FY2025 earnings at ($5.96) EPS, Q1 2026 earnings at ($1.18) EPS, Q2 2026 earnings at ($1.03) EPS, Q3 2026 earnings at ($0.91) EPS, Q4 2026 earnings at ($0.84) EPS and FY2026 earnings at ($3.90) EPS.

Other research analysts have also issued reports about the company. Oppenheimer reaffirmed an "outperform" rating and set a $15.00 target price on shares of KALA BIO in a research report on Monday, June 2nd. LADENBURG THALM/SH SH began coverage on KALA BIO in a research report on Friday, July 11th. They set a "buy" rating and a $12.00 target price for the company. Finally, Wall Street Zen lowered KALA BIO from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, KALA BIO currently has a consensus rating of "Buy" and an average price target of $13.00.

KALA BIO Trading Down 2.2%

NASDAQ:KALA traded down $0.19 during trading hours on Friday, hitting $8.39. 151,978 shares of the company were exchanged, compared to its average volume of 87,956. The stock has a market capitalization of $58.91 million, a price-to-earnings ratio of -1.24 and a beta of -1.81. The company has a current ratio of 2.10, a quick ratio of 2.10 and a debt-to-equity ratio of 3.19. KALA BIO has a one year low of $2.92 and a one year high of $11.20. The company has a fifty day simple moving average of $5.98 and a 200 day simple moving average of $5.60.

KALA BIO (NASDAQ:KALA - Get Free Report) last announced its quarterly earnings results on Friday, August 8th. The company reported ($1.71) EPS for the quarter, beating analysts' consensus estimates of ($1.82) by $0.11.

Insiders Place Their Bets

In other KALA BIO news, Director Mark T. Iwicki sold 13,227 shares of the stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $4.01, for a total transaction of $53,040.27. Following the completion of the sale, the director directly owned 258,433 shares in the company, valued at approximately $1,036,316.33. This trade represents a 4.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last three months, insiders sold 41,335 shares of company stock worth $162,876. Company insiders own 8.32% of the company's stock.

Institutional Trading of KALA BIO

Several large investors have recently made changes to their positions in the company. XTX Topco Ltd acquired a new stake in shares of KALA BIO in the 2nd quarter valued at about $62,000. Geode Capital Management LLC grew its stake in shares of KALA BIO by 2.8% in the 2nd quarter. Geode Capital Management LLC now owns 56,367 shares of the company's stock valued at $268,000 after buying an additional 1,534 shares during the period. AIGH Capital Management LLC grew its stake in shares of KALA BIO by 52.8% in the 2nd quarter. AIGH Capital Management LLC now owns 300,000 shares of the company's stock valued at $1,428,000 after buying an additional 103,650 shares during the period. Woodline Partners LP acquired a new stake in shares of KALA BIO in the 1st quarter valued at about $1,483,000. Finally, ADAR1 Capital Management LLC grew its stake in shares of KALA BIO by 35.7% in the 1st quarter. ADAR1 Capital Management LLC now owns 298,955 shares of the company's stock valued at $1,713,000 after buying an additional 78,582 shares during the period. 24.61% of the stock is currently owned by institutional investors and hedge funds.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.